Randomized Controlled Trials on Intracerebral Hemorrhage: A Cross Sectional Retrospective Analysis of CONSORT Item Adherence

Kirstin Jauch¹, Ana Kowark², Mark Coburn³, Hans Clusmann¹ and Anke Höllig³*

¹ Department of Neurosurgery, University Hospital Aachen, RWTH Aachen University, Aachen, Germany; ² Department of Anaesthesiology, University Hospital Aachen, RWTH Aachen University, Aachen, Germany

Object: Intracranial hemorrhage (ICH) is the second most common cause of stroke but still there is little consolidated knowledge about the optimal treatment strategies (e.g., the benefit of surgical evacuation). We evaluated the current randomized controlled trials (RCTs) on primary ICH (01.2013–03.2017) according to their fulfillment of the CONSORT statement’s criteria (published in 2010) –as a marker of transparency and quality of study planning and realization.

Methods: A Pubmed and a Cochrane database (including clinicaltrials.gov) search was carried out (01.2014–3.2017, respectively 01.2013–12.2013). Abstracts were screened for inclusion. Eligible full text manuscripts were assessed for the implementation of the CONSORT criteria. Citation frequencies and impact factors of the journals were related to ratio of CONSORT criteria fulfillment. Further, the risk of bias according to the Risk of bias tool 2 (RoB 2) was assessed.

Results: Overall 3097 abstracts were screened for inclusion; 39 studies were suitable for final analysis. A mean fulfillment ratio of 51% (±28%) was found. A high correlation between impact factor and adherence to CONSORT criteria was shown ($r = 0.7664; p < 0.0001$). Citation frequency per year was related to ratio of CONSORT item fulfillment ($r = 0.6747; p < 0.0001$) and to the impact factor of the publishing journal ($r = 0.7310; p < 0.0001$). Of note, the items 10 (randomization: implementation) and 21 (generalizability) showed particularly high rates of non-fulfillment (87 and 85%). The majority of studies (95%) complied with item 2b (specific objectives or hypotheses), but strikingly objectives were mostly described vaguely. Other essential criteria such as sample size determination, definition of outcome parameters, and participant flow were only fulfilled weakly (51, 54, and 39%).

Conclusions: Over 20 years after its inception there is still weak adherence to the CONSORT statement. As a consequence, conclusions are hampered by inadequate planning and/or reporting. Particularly with respect to pathologies as ICH lacking clear, evidence-based guidelines adherence to the CONSORT statement might improve research quality in order to define valuable treatment strategies.

Keywords: hemorrhagic stroke, intracerebral hemorrhage, CONSORT statement, randomized controlled trials, transparent reporting
INTRODUCTION

Intracranial hemorrhage (ICH) is the second most common cause of stroke; the overall global burden of hemorrhagic stroke (ICH and subarachnoid hemorrhage) including deaths and DALYs (disability-adjusted life years) is higher than in ischemic stroke, although ischemic stroke accounts for nearly twice as much number of incidents (1, 2). Of note, the DALYs lost due to hemorrhagic stroke are almost twice as high than those lost due to ischemic stroke (62,842,896 vs. 39,389,408 years, data for 2010) (1). Thus, ICH is a condition with huge impact on the patient’s individual fate, but also accounts for enormous social and socio-economic consequences. There is still debate concerning the optimal medical therapy. Data on surgical treatment are conflicting: There is no consensus on the question which subgroup of patients actually benefits from a surgical intervention, if there is a benefit. Even the large STICH trials (3, 4) were not able to clarify this subgroup sufficiently and the conclusions especially drawn from the STICH trials are still debated controversially (5–7).

In general, problems arise from the fact that the term “ICH” summarizes heterogeneous entities that vary concerning genetic and lifestyle risk factors (8–10) and consecutively show different bleeding locations. Further timing of surgical intervention, indications for surgery, basic therapeutic strategies (e.g., blood pressure control) differ between the treating medical facilities. Some of these aspects may be hardly avoided planning a trial on ICH treatment.

There are also methodological aspects which have to be taken into account. Despite some disadvantages randomized controlled trials (RCT) still are regarded as the “gold standard” for a clinical research (11, 12). Treatment guidelines are usually based upon the results of RCTs or on systematic reviews/metaanalyses which in turn rest on the results acquired by RCTs and results of methodologically weak RCTs may alter their conclusions erroneously (13). Therefore, methodological quality is essential; this includes high quality of reporting (14). In 1998 the CONSORT (Consolidated Standards of Reporting Trials) statement (revised in 2001 and 2010) was published in order to provide a guideline for the reporting of RCTs (15–17). Basically, the CONSORT statement was intended to maximize research transparency in order to enable authors, reviewers, editors and finally readers to assess the methodology and consecutively to interpret the results properly. In fact, adherence to the CONSORT statement’s criteria is associated with improvements in the quality of reports of RCTs (18–21). Concerning for example neurosurgical trials (which some of the ICH intervention trials are) both the quality of design and reporting is low (22).

OBJECTIVE

Here, we evaluated RCTs on primary ICH according to their fulfillment of the current CONSORT statement’s criteria. Furthermore, we correlated the impact factor of the journal and the citation frequency with the ratio of CONSORT statement’s criteria fulfillment. Thus, we aimed to analyze the transparency of reporting in ICH trials to identify targets in order to improve planning and reporting of ICH trials.

METHODS

Study Design

We performed a cross sectional retrospective study (conducted at the University Hospital, RWTH Aachen University, Germany) and reported the data according to the STROBE statement (23). At first, we analyzed the literature on ICH from January 2014 to March 2017 (literature search: 04-23-2017) and included the timespan from January 2013 to December 2013 later on (literature search: 06-16-2017) to increase the number of articles available for inclusion. The abstracts were acquired using a Pubmed and a Cochrane database (including clinicaltrials.gov) search with the following search terms: [(cerebral hemorrhage) OR (hemorrhagic stroke) OR (intracerebral hemorrhage) OR (intracranial hemorrhage) OR (intracranial bleeding) OR (intracerebral hematoma) OR (intracranial hematoma)] AND [(randomized controlled) OR randomized OR RCT]. Two authors (KJ and AH) screened all abstracts for inclusion (applying the following inclusion criteria: randomized controlled clinical trial on patients with acute primary ICH). Therefore, abstracts of trials on secondary ICH (e.g., trauma-associated), experimental studies, review articles etc. were excluded (for details see Flowchart; Table 1). Discrepancies regarding the study allocation were discussed with a second author (AH). Afterwards, the eligible full text manuscripts were assessed for the implementation of the CONSORT criteria (see below).

TABLE 1 | Flowchart showing the screening of abstracts and selection process for articles included and excluded in the current study.

| Pubmed search | Cochrane search | Fulltext articles excluded: |
|---------------|----------------|----------------------------|
| 01.01.2013 – 31.12.2013 | 01.01.2014 – 31.03.2017 | n = 3 |
| 1,326 | 870 | 5 (duplicates) |
| Abstracts analyzed | Abstracts excluded | n = 3047 |
| n = 3,359 | n = 3,265 (no study on primary ICH) | n = 3 (no RCT) |
| n = 963 (no RCT) | n = 18 (experimental study) | n = 5 |
| n = 683 (conference paper) | n = 60 (duplicate listing) | n = 3 (published after 03/2017) |
| n = 37 (other reasons) | n = 13 (no fulltext in English) | n = 5 (duplicates) |
| n = 39 | n = 8 (published after 03/2017) | n = 3 (published after 03/2017) |
| Abstracts included | Fulltext articles excluded: | Studies Included |
| n = 30 | n = 3 |
| n = 50 |
Data Extraction
At first, a data sheet consisting of standardized categories representing the CONSORT items was elaborated (KJ, AK, and AH) to ensure an evaluation as objective as possible. The eligible full text articles (including available supplements) were examined for their fulfillment of the 37 CONSORT items by one author (KJ). About 10% of the items were cross-checked randomly by another author (AH). Further, in case of ambiguity the specific item was discussed between at least two of the authors (KJ, AH) and a decision was made together. Every item was classified as “fulfilled” (f), “not fulfilled” (nf) or “not applicable” (na). The classification “na” was feasible for items which are not mandatory, e.g., item 7b “When applicable, explanation of any interim analyses and stopping guidelines.”

Additionally, the risk of bias of each study was assessed using the revised Cochrane risk of bias (RoB) tool 2 (24, 25). For statistical purposes a “low risk” of bias was defined as a score of one, “some concerns” were defined as a score of two and a “high risk” was defined as a score of three. The sum scores (summation of the single domain scores) were documented and related with CONSORT criteria adherence.

The citation frequency and the impact factor of the journal (for the year the manuscript was published) were assessed using the Web of Science (Clarivate Analytics). Citation frequency per year was calculated to eliminate the bias derived from articles which are available for a longer period of time. Four studies (26–29) had to be excluded for additional analyses as it was not listed in the WEB of Science.

STATISTICAL METHODS
We reported the percentages of CONSORT criteria adherence for each item. Additionally, summary statistics were calculated and graphically presented. Further, RoB scores were related with CONSORT criteria fulfillment. Citation frequency and citation frequency per year were correlated with impact factor and adherence of CONSORT criteria fulfillment: Due to non-linear relationships we computed the Spearman’s rank-order correlation (computing the coefficient r) and reported the corresponding p-value. For better visualization due to non-linear relationship logarithmic axes were used. Therefore, for the graphical representation citation frequencies with the value zero were set to 0.001. All our statistical analyses were performed using GraphPad Prism 8.2.0 (GraphPad Prism Software Inc., La Jolla, CA, USA). A p-value of 0.05 was regarded statistically significant.

RESULTS
We analyzed a total of 3,097 abstracts; 1,157 had to be excluded due to the following reasons: no study on primary ICH (n = 1,265), no RCT (n = 963), experimental study (n = 18), duplicate listing (n = 60), no full text in English (n = 13), published after 03/2017 (n = 8), other reasons (n = 37). Because of duplicate listing five more studies had to be excluded. Thus, a total of 34 studies was available for full-text analysis. After full-text analysis three studies turned out not to be RCTs and three further studies were identified as published after March 2017. Therefore, 39 studies finally were analyzed (see Flowchart; Table 1) (4, 26–63). For further information on studies, specific interventions and outcome measures please see Supplemental Data File.

On average only 51% (±28%; n = 741) of the requested CONSORT items were fulfilled: 49% of the included studies (n = 19) complied with <50% of the CONSORT criteria (Figure 1). For each specific CONSORT item the percentage adherence of all 39 RCTs analyzed is shown in Tables 1, 2. Excluding the optional items and those only applicable for a portion of the studies (items 3b, 6b, 7b, 11b, 12b, 17b, 23, and 24) resulted in an adherence of 59% (±24%; n = 670).

Of note, the items 10 (randomization: implementation) and 21 (generalizability) showed particularly high rates of non-fulfillment (87 and 85%). The majority of studies (95%) complied with item 2b (specific objectives or hypotheses), but strikingly objectives were mostly described vaguely. Applying a strict interpretation of item 2b (demanding a clear hypothesis including outcome specification) only 23% would have fulfilled this item. Other essential criteria such as sample size determination, definition of outcome parameters and participant flow were only fulfilled weakly (51, 54, and 39%). Less than a 50% adherence was demonstrated for 43% (n = 16) of the CONSORT items (excluding the optional ones −3b, 6b, 7b, 11b, 12b, 17b, 23, and 24-: in 31% of the mandatory items −n = 9- a fulfillment rate of <50% was seen) (Table 2).

Examining the relationship of the journals’ impact factor with the fulfillment of CONSORT criteria a distinct correlation (r = 0.7664; p < 0.0001) was shown (Figure 2). Citation frequency was slightly related to ratio of CONSORT item fulfillment (r = 0.6605; p = 0.0001; expressed as citation frequency per year: r = 0.6747; p < 0.0001) (Figure 3). The citation frequency was highly associated with the impact factor of the publishing journal (r = 0.7599; p < 0.0001) (Figure 4). For better visualization due to non-linear relationships we computed the Spearman’s rank-order correlation (computing the coefficient r) and reported the corresponding p-value. A p-value of 0.05 was regarded statistically significant.
Table 2 shows the numbers and percentage adherence of the 39 RCTs analyzed to each CONSORT item.

| Item description | Items fulfilled; percentage |
|------------------|----------------------------|
| **Title and abstract** | |
| 1a Identification as a randomized trial in the title | n = 16; 41.03% |
| 1b Structured summary of trial design, methods, results, and conclusions | n = 15; 38.46% |
| **Introduction** | |
| Background and objectives | |
| 2a Scientific background and explanation of rationale | n = 37; 94.87% |
| 2b Specific objectives or hypotheses | n = 37; 94.87% |
| **Methods** | |
| Trial design | |
| 3a Description of trial design (such as parallel, factorial) including allocation ratio | n = 31; 79.49% |
| 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons | n = 2; 5% |
| Participants | |
| 4a Eligibility criteria for participants | n = 34; 87.18% |
| 4b Settings and locations where the data were collected | n = 28; 71.79% |
| Interventions | |
| 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | n = 35; 82.05% |
| Outcomes | |
| 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | n = 21; 53.85% |
| 6b Any changes to trial outcomes after the trial commenced, with reasons | n = 1; 2.56% |
| Sample size | |
| 7a How sample size was determined | n = 20; 51.28% |
| 7b When applicable, explanation of any interim analyses and stopping guidelines | n = 4; 10.26% |
| **Randomization** | |
| Sequence generation | |
| 8a Method used to generate the random allocation sequence | n = 28; 71.79% |
| 8b Type of randomization; details of any restriction (such as blocking and block size) | n = 8; 20.51% |
| Allocation concealment mechanism | |
| 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | n = 11; 28.21% |
| Implementation | |
| 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | n = 5; 12.82% |
| Blinding | |
| 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | n = 24; 61.54% |
| 11b If relevant, description of the similarity of interventions | n = 2; 5.13% |
| Statistical methods | |
| 12a Statistical methods used to compare groups for primary and secondary outcomes | n = 22; 58.97% |
| 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses | n = 16; 41.03% |
| **Results** | |
| Participant flow (a diagram is strongly recommended) | |
| 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome | n = 15; 38.46% |
| 13b For each group, losses and exclusions after randomization, together with reasons | n = 16; 41.03% |
| Recruitment | |
| 14a Dates defining the periods of recruitment and follow-up | n = 33; 84.62% |
| 14b Why the trial ended or was stopped | n = 18; 46.15% |

(Continued)
TABLE 2 | Continued

| Item description | Items fulfilled; percentage |
|------------------|-----------------------------|
| **Baseline data** |                             |
| 15 A table showing baseline demographic and clinical characteristics for each group | n = 32; 82.05% |
| 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | n = 23; 58.97% |
| **Outcomes and estimation** |                             |
| 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | n = 27; 69.23% |
| 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended | n = 20; 51.28% |
| **Ancillary analyses** |                             |
| 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | n = 20; 51.28% |
| **Harms** |                             |
| 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | n = 20; 51.28% |
| **Discussion** |                             |
| Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | n = 31; 79.49% |
| Generalizability 21 Generalizability (external validity, applicability) of the trial findings | n = 6; 15.38% |
| Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | n = 39; 100% |
| **Other information** |                             |
| Registration 23 Registration number and name of trial registry | n = 15; 38.46% |
| Protocol 24 Where the full trial protocol can be accessed, if available | n = 11; 28.21% |
| Funding 25 Sources of funding and other support (such as supply of drugs), role of funders | n = 20; 51.28% |
| A total of | n = 741; 51.35% |

Indeed, the CONSORT statements are guidance for authors, editors, and reviewers to improve transparency, and although each item should theoretically be reported, each item cannot be considered as having the same importance. For example, items related to “randomization,” which are essential to evaluate the risk of bias of the study, could be considered more important than items related to “scientific background and explanation of rationale.” It is far more relevant to report the completeness of reporting for each item separately and explore its evolution over time.

The risk of bias tool (25) and its revised version (24) aim to judge the risk of bias in randomized trials according to five domains (Domain I: Randomization Progress; Domain II: Deviations from intended interventions; Domain III: Missing outcome data; Domain IV: Measurement of the outcome; Domain V: Selection of the reported results). We analyzed the included studies according to RoB 2: The RoB sum score and CONSORT criteria fulfillment correlated very weakly ($r = 0.4758; p = 0.0022$). A graphic illustration of the RoB sum scores is shown in Figure 5.

**DISCUSSION**

Despite the clinical urge for evidence based guidelines concerning the treatment of ICH there is still very weak adherence to the CONSORT statement (average: 51%). The impact factor of the publishing journal and the citation frequency correlate with the ratio of CONSORT item fulfillment.
There are some important items, which in general demonstrate low adherence rates (e.g., details of randomization). Of note, substantial items (such as sample size determination, definition of outcome parameters and participant flow) were only fulfilled weakly (55, 61, and 45%).

In 2011 Kiehna et al. reported a low CONSORT criteria adherence score of neurosurgical RCTs (published 2006–2007 in: Journal of Neurosurgery; Neurosurgery; Surgical Neurology; Journal of Neurology, Neurosurgery and Psychiatry; Acta Neurochirurgica) compared to the three leading general medicine journals (Journal of the American Medical Association; Lancet; The New England Journal of Medicine) (mean score of 26.4 vs. 41 out of 44) (64). Similarly, Mansouri et al. published an analysis on RCTs in neurosurgery (2000–2014) using specific search terms (22). It was shown that the reporting quality in general was low (median CONSORT score of 36 out of 44) and that specific items such as blinding, sample size calculation, allocation concealment and protocol implementation were reported rarely. Sample size calculation, which is essential for an RCT to produce a relevant conclusion, was documented in only 20–34.2% (depending on subspecialty). The reporting of this specific actually has improved (reporting in 51% of the studies included). But generally, in line with the prior results—more than 20 years after the first publication of the CONSORT statement—we demonstrated substantial paucities regarding the planning and reporting of RCTs on ICH. In fact, there are some studies with a reporting at a high quality level, but lack fundamental issues such as a randomization, sample size calculation, and transparent participant flow allowing the reader to understand the number of patients analyzed including drop-outs and specific reasons. Thus, not only the mere ratio of adherence has to be taken into account. This is supported by a statement of the member of the CONSORT steering group: “...although each item should theoretically be reported, each item cannot be considered as having the same importance” (65).

However, in contrast to the above mentioned studies our analysis was based on a specific pathology, ICH, and was not only limited to RCTs published in neurosurgical journals but also incorporates RCTs published in journals focused on other areas such as critical care or general medicine.
ICH is the second most common cause of stroke and accounts for a high mortality and morbidity. Still, the median case fatality at 1 month is as high 40.4% (2). However, due to the heterogeneous disease patterns (in the framework of different localizations, risk factors, clinical presentations etc.) it is challenging to conceive an RCT representing the entire spectrum of ICH. Therefore, analyses of subgroups (which has already been done) may be feasible to increase the evidence for ICH treatment. Additionally, a special CONSORT extension addressing non-pharmacological interventions was published in 2017 (66), which has not been taken into account as it was published in July 2017 (studies have been included from 01/2013 to 03/2017). However, many items –especially the essential ones such as randomization, sample size calculation, definition of outcome measures– overlap.

For other major specialties such as anesthesiology, critical care, or surgery the CONSORT criteria adherence has also been analyzed (67–70). In general, all studies report a demand for improvement of planning and reporting. Even if the analyses are limited to high-ranked journals non-adherence to the CONSORT statement (especially concerning methodological quality domains) is frequent (71, 72); albeit these studies only examined the abstracts published. Journal endorsement of the CONSORT statement was attested to improve the quality of reporting in terms of completeness and transparency (20, 21). However, there are still scarcities and inaccuracies as adherence is not always monitored rigorously (21).

Specific items–regardless of the CONSORT criteria– have been evaluated extensively, such as intervention description and outcome measures (73, 74): It has been shown, that only 13% of articles published in the top five medical journals (New England Journal of Medicine, Lancet, JAMA, The BMJ, and Annals of Internal Medicine) October 2015 to January 2016 were "perfectly" reported, meaning that the original primary and secondary outcome measures were reported as initially prespecified (74). The authors have found that 354 outcome were not reported and that 357 outcomes were reported that in the forefront had not laid down in the protocol (74). Concerning intervention of 137 interventions reported in 2009 in the leading 6 medical journals only 53 (39%) were adequately described (73). Again, this may influence the interpretation of the results presented misleadingly, replication of trials is hampered and interventions intended as therapeutic procedure may not be conducted properly. In conclusion, inaccuracies in planning and reporting of RCTs are frequent and can bias their interpretation severely. The endorsement of the CONSORT statement may improve the reporting of RCTs.

There are enormous problems at different stages of research, which are not always solved by adherence to the CONSORT criteria. For example, when planning a new trial only 11 out of 24 authors were not aware of the Cochrane reviews that already existed (75). Methodological flaws, such as inadequate or unclear concealment of treatment allocation (18, respectively, 26% evaluating 234 trials published in the major general medical) (76), are frequent. These are only some aspects which result in the “production and reporting of avoidable waste in research” (77). Due to limited resources, ethical issues and consequences concerning clinical algorithms the problem of inaccurately planned and reported research must be tackled. Adherence to the CONSORT guidelines may not be the entire solution but at least a helpful start. Here, we present the data on 39 RCTs concerning ICH. Our analysis is limited to the fact that the interpretation of the CONSORT criteria sometimes is objective and the judgement between different observers may vary. We performed a cross-check of 10% of the data and uncertainties were discussed between at least two of the authors. Anyway, there is bias derived from the fact, that mainly one author was responsible for the judgement of adherence to the CONSORT criteria. Further, some of the criteria are not binary parameters but leave some margin for interpretation. Again, judgement may depend distinctly on the individual observer. Further, our analysis does not weight the specific items.

CONCLUSION

Over 20 years after its inception there is still weak adherence to the CONSORT statement: Inadequate planning and/or reporting is frequent and essential information such as sample size calculation and clear definitions of outcome measures are often missing. As a consequence, conclusions based on these trials are regularly hampered. Reviewers and readers are not able to classify the results properly. Due to incomplete reporting scientist are not able to replicate the trials. Particularly with respect to pathologies as ICH lacking clear, evidence-based guidelines endorsement of the CONSORT statement and a consequent audit of its adherence might improve research quality in order to define valuable treatment strategies.

DATA AVAILABILITY

The data analyzed during this study are included in this published article (references of analyzed articles, ratios of adherence). Additional information (data on
citation frequencies, impact factors, ratios of non-fulfillment...) is available from the corresponding author on reasonable request.

AUTHOR’S NOTE

Portions of this work were presented in abstract form at the “Arbeitstagung NeuroIntensiv Medizin—ANIM” 2019 in Berlin, Germany, January 18, 2019.

AUTHOR CONTRIBUTIONS

AH conceived and designed the study. AK and MC helped to elaborate a revised study plan. KJ, AK, and AH elaborated a data sheet of standardized categories representing the CONSORT items. KJ and AH screened the abstracts and analyzed the data. KJ examined the full-text articles and drafted the first version of the manuscript. AH cross-checked 10% of the screened items. In case of ambiguity the specific item was discussed between KJ and AH. AH, AK, MC, and HC critically revised interpretation of the data and revised the first draft of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00991/full#supplementary-material

Supplemental Data File | Summary of the studies included: Title, Journal (including year of publication), intervention and primary outcome.
26. Arumugam A, Rahman ANA, Theophilus SC, Sharifiudin A, Abdullah JM. Tranexamic acid as antifibrinolytic agent in non traumatic intracerebral hemorrhages. *Malays J Med Sci.* (2015) 22:62–71.

27. Zhao Y, Wan X-B. Observation on the application of emergency green channel in clinical rescue of acute cerebral hemorrhage patients. *Biomed Res.* (2012) 23:1392–5.

28. Saekhu M, Ibrahim N, Timan IS, Majdij AS, Muttaqin Z, Ronokusumo TAS, et al. MMP-9, brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the implementation of tigecycline. *Med J Indonesia.* (2016) 25:221–7. doi: 10.13181/mj.v25i4.1520

29. Johnson JR, Idris Z, Abdullah JM, Alias A, Haspni MSM. Prevalence of shunt dependency and clinical outcome in patients with massive intraventricular haemorrhage treated with endoscopic washout and external ventricular drainage. *Malays J Med Sci.* (2017) 24:40–6. doi: 10.21315/mjms2017.24.1.5

30. Anderson CS, Healey E, Huang Y, Wang J, Staph C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med.* (2013) 368:2355–65. doi: 10.1056/NEJMoa1214609

31. Baharouglu MI, Cordonnier C, Salman RA-S, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet.* (2016) 387:2605–13. doi: 10.1016/S0140-6736(16)30392-0

32. Bodelle B, Klein E, Naguib NNN, Bauer RW, Korl JM, Al-Butnij M, et al. Acute intracranial hemorrhage in CT: benefits of sinogram-aided iterative reconstruction techniques. *AJNR Am J Neuroradiol.* (2014) 35:445–9. doi: 10.3174/ajnr.A3801

33. Butcher KS, Jeerkathal T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. *Stroke.* (2013) 44:620–6. doi: 10.1161/STROKEAHA.111.001188

34. Chen C-C, Chen X, Li T-C, Lin H-L, Chu Y-T, Lee H-C, et al. PG2 for patients with acute spontaneous intracerebral hemorrhage: a double-blind, randomized, placebo-controlled study. *Sci Rep.* (2017) 7:45628. doi: 10.1038/srep45628

35. Dun Z, Zhu S, Jiang H. Benefits of a frame-based stereotactic surgical planning system for the treatment of spontaneous intracerebral haematomas. *J Int Med Res.* (2013) 41:1550–9. doi: 10.1177/0300060513498022

36. Feng Y, He J, Liu B, Yang L, Wang Y. Endoscope-assisted keyhole technique for hypertensive cerebral hemorrhage in elderly patients: a randomized controlled study in 184 patients. *Turk Neurosurg.* (2016) 26:84–9. doi: 10.5137/1014-5147.TJN1609-14.0

37. Gong FT, Yu LP, Gong YH, Zhang YX, Wang ZG, Yan CZ. Blood-pressure lowering in patients with acute intracerebral hemorrhage. *Neurology.* (2010) 75:1033–43. doi: 10.1056/NEJMoa1005699

38. Guo R, Li H, Lin S, Ma J, Guo R, Ma L, et al. Perioperative antihypertensive treatment of hypertensive basal ganglia hemorrhage. *Br J Neurosurg.* (2014) 28:478–82. doi: 10.3109/02686897.2013.869548

39. Moussa WM, Khedr W. Decompressive craniectomy and expansive duraplasty with evacuation of hypertensive intracerebral hematoma, a randomized controlled trial. *Neurosurugy Rev.* (2017) 40:115–27. doi: 10.1007/s10143-016-0743-6

40. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med.* (2016) 375:1033–43. doi: 10.1056/NEJMoa1605460

41. Sprigg N, Renton CJ, Dineen RA, Kwong Y, Bath PMW. Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN08867461). *J Stroke Cerebrovas Dis.* (2014) 23:1312–8. doi: 10.1016/j.jstrokecerebrovasdis.2013.11.007

42. Steinier T, Poli S, Griebe M, Hüsing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. *Lancet Neurol.* (2016) 15:566–73. doi: 10.1016/S1474-4422(16)00101-9

43. Su X, Zheng K, Ma Q, Huang J, He X, Chen G, et al. Effect of local mild hypothermia on regional cerebral blood flow in patients with acute intracerebral hemorrhage assessed by 99mTc-ECD SPECT imaging. *J Vasc Technol.* (2013) 23:101–9. doi: 10.3233/XST-140473

44. Trapano P, Hanley D, Betz J, Hoffer A, Engh J, Carter R, et al. ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain hemorrhage: a multicenter randomized controlled trial. *Stroke.* (2016) 47:2749–55. doi: 10.1161/STROKEAHA.116.013837

45. Wang H-Q, Bao C-L, Jiao Z-H, Dong G-R. Efficacy and safety of local hypothermia on regional cerebral blood flow in patients with acute intracerebral hemorrhage: a randomized controlled study. *Strok Res.* (2013) 22:328–34. doi: 10.1097/01.STR.0000446107.03920.92

46. Miao ZL, Jiang L, Xu X, Chen KL, Lu XJ. Microsurgical treatment assisted aspiration and electro-acupuncture for hypertensive putaminal hemorrhage related to vitamin K antagonists (INCH): a randomised trial. *Lancet Neurol.* (2016) 15:566–73. doi: 10.1016/S1474-4422(16)00101-9

47. Zhao W, Zhu C, Kong Z, Xu Y, Liu G, et al. The clinical effect of people with hemorrhagic stroke. *Stroke.* (2013) 14:19. doi: 10.1186/1471-2253-14-19

48. Zhang Y, Al-Aref R, Fu H, Yang Y, Feng Y, Zhao C, et al. Neuronavigation-assisted aspiration and electro-acupuncture for hypertensive putaminal hemorrhage.
hemorrhage: a suitable technique on hemiplegia rehabilitation. Turk Neurosurg. (2017) 27:500–8. doi: 10.5137/1019-5149.JTN.16456-15.1
61. Yang G, Shao G. Clinical effect of minimally invasive intracranial hematoma in treating hypertensive cerebral hemorrhage. Pak J Med Sci. (2016) 32:677–81. doi: 10.12669/pjms.323.9533
62. Kerebel D, Joly L-M, Honnart D, Schmidt J, Galanaud D, Negrier C, et al. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal. Crit Care. (2013) 17:R4. doi: 10.1186/cc11923
63. Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. (2017) 389:603–11. doi: 10.1016/S0140-6736(16)32410-2
64. Kiehna EN, Starke RM, Pouratian N, Dumont AS. Standards for reporting randomized controlled trials in neurosurgery. J Neurosurg. (2011) 114:280–5. doi: 10.3171/2010.8.JNS091770
65. Boutron I. Commentary on “Compliance of Randomized Controlled Trials Published in General Surgical Journals With the CONSORT 2010 Statement”. Ann Surg. (2019) 269:e28. doi: 10.1097/SLA.0000000000003158
66. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. Ann Intern Med. (2017) 167:80–7. doi: 10.7326/M17-0046
67. Stevanovic A, Schmitz S, Rossaint R, Schürholz T, Coburn M. CONSORT item reporting quality in the top ten ranked journals of critical care medicine in 2011: a retrospective analysis. PLoS ONE. (2015) 10:e0128061. doi: 10.1371/journal.pone.0128061
68. Sinha S, Sinha S, Ashby E, Jayaram R, Grocott MPW. Quality of reporting in randomized trials published in high-quality surgical journals. J Am Coll Surg. (2009) 209:565-571.e1. doi: 10.1016/j.jamcollsurg.2009.07.019
69. Münter NH, Stevanovic A, Rossaint R, Stoppe C, Sanders RD, Coburn M. CONSORT item adherence in top ranked anaesthesiology journals in 2011: a retrospective analysis. Eur J Anaesthesiol. (2015) 32:117–25. doi: 10.1097/EJA.0000000000000176
70. Hoffmann TC, Erueti C, Glasziou PP. Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ. (2013) 347:f3755. doi: 10.1136/bmj.f3755
71. Ioannidis JP, Caplan AL, Dal-Ré R. Outcome reporting bias in clinical trials: why monitoring matters. BMJ. (2017) 356:j4080. doi: 10.1136/bmj.j408
72. Cooper NJ, Jones DR, Sutton AJ. The use of systematic reviews when designing studies. Clin Trials. (2005) 2:260–4. doi: 10.1191/1740774505ct090oa
73. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. (2005) 330:1057–8. doi: 10.1136/bmj.38413.576713.AE
74. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. (2009) 374:86–9. doi: 10.1016/S0140-6736(09)60329-9

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Jauch, Kowark, Coburn, Claussmann and Höllig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.